Recent Recurrent Melanoma News

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 24, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma... Continue Reading

Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug (May 22, 2013)

Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by... Continue Reading

Combined Targeted Therapy Safe and Effective in Metastatic Melanoma (October 24, 2012)

Treatment with a combination of two targeted agents—dabrafenib, which targets BRAF, and trametinib, which targets MEK—in patients with metastatic melanoma and BRAF V600 mutations was safe and improved... Continue Reading

Next Page »